GBCC, formerly known as Interpark Bioconvergence Corporation, is one of the earliest organizations developing patient derived organoids (PDOs) in global scale. We have over 500 PDOs from lung, gastric and colorectal cancer patients and are also developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our CRISPR-based PDO platform. Beyond cancer, GBCC is conducting research on brain organoid from human iPSC for disease modeling and regenerative medicine. In addition, we are developing human derived probiotics not only as health functional foods but also therapeutic agents through functional evaluation using our colon PDOs. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built Asia’s largest repository of PDOs with next-generation sequencing of over 600 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built one of Asia’s largest repository of PDOs with next-generation sequencing of over 800 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | xxx
GenAIz
x | GenAIz unlocks the value of life sciences enterprise data, connecting systems with AI-powered intelligent solutions so teams can act with clarity, confidence, and speed. To do this, we’ve created a novel, ethical, and data compliant AI solution that massively increases workflow efficiency across pharmaceutical and life sciences applications.
GELITA AG
GELITA is the leading company for manufacturing and marketing collagen proteins. With its headquarters in Eberbach, Germany, GELITA provides customers around the world with products of the highest standard, comprehensive technical expertise and sophisticated solutions. More than 20 sites and a global expert network ensure that state-of-the-art know-how is always available for customers. 150 years of experience in the field of collagen proteins are the basis of GELITA’s performance. A strong requirement for innovation is the driving force of the family-owned company that is always looking for new solutions for food, dietary supplements, pharmaceutical industries, as well as many other technical applications.
Evaluate
Evaluate radically transforms your confidence in strategic portfolio decisions. We are the leading provider of commercial intelligence and predictive analytics for the global pharmaceutical industry. We work with the world’s largest pharmaceutical corporations, financial services firms, management consultancies and service providers, as well as a wide range of innovative biotech and medtech companies. From an overview of the broader market to a detailed product or company analysis, Evaluate’s integrated platform is designed to take you from exploration to full understanding as quickly and accurately as possible. We help you: – Identify competitor developments and likely time to market – Forecast patient populations and product sales for a potential lead asset – Undertake NPV assessments based on modelling discounted cash flows – Manage clinical trial costing Evaluate offers a pharmaceutical Consulting & Analytics service designed to help clients address unique scientific, clinical and commercial challenges. Our pharmaceutical consulting services provide insight into: – Market Analysis & Competitor Intelligence – Corporate Strategy & Franchise Planning – Market Expansion & Forecasting – Mergers & Acquisition – New Product Development – Market Access and Pricing – Commercialization Evaluate is now a Norstella company: an organization that helps to ease and accelerate patient access to life-changing therapies. | Evaluate radically transforms your confidence in strategic portfolio decisions. In biopharma, making the right decisions has an incredible impact on patients’ lives. Making those decisions requires a deep understanding of your market; from identifying opportunities and mitigating risk to evaluating assets and pipelines. Evaluate provides a complete and dynamic view of the pharmaceutical market, with innovative solutions that bring together technology, real world data, and deep expertise to help you make portfolio decisions that drive growth. | Evaluate provides trusted commercial intelligence and forecasting models for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global biopharma market to drive better decisions. Evaluate’s solutions give you the time and confidence to turn understanding into insight, and insight into action. Market Sizing & Forecasting: Evaluate’s suite of forecasting solutions enables you to make confident investment, partnering, and commercial decisions. Gold-standard consensus forecasts provide an unmatched view into your markets, while custom forecast models, and proprietary analogs enable you to develop informed forecasts on your key assets. The result? A comprehensive view of the market – and your place in it. Business Development & Licensing: Every deal is different and requires a clear view of potential partners, comparable deals, and market potential. To support you, we go beyond asset assessment. Our solutions provide a systematic approach to enable you to compare candidates based on commercial, clinical, and scientific criteria such as market novelty, potential revenue, competitive intensity, and partner suitability. Portfolio Optimization & Asset Strategy: In an ever-evolving market landscape, you must understand the intricacies of clinical and commercial differentiation. Our comprehensive suite of solutions and insights give you the competitive edge you need to navigate the market’s complexities, optimize your pipeline, develop comprehensive scenario planning, and prioritize the right indications. Competitive Intelligence: For biotech and pharma companies alike, a comprehensive view of the competitive landscape is vital. Evaluate’s blend of data-driven solutions and expert analysis provide real-time tracking, analysis, and strategic intelligence to support decision-making processes across drug development, manufacturing, and market competition. So nothing need take you by surprise. Consulting & Analytics: Evaluate’s custom analytics team help you to address unique commercial challenges. We answer key asset, portfolio, and corporate strategy-related questions, powered by the combined resources of Norstella. With access to extensive data assets and experience across therapy areas and modalities, we partner with you to provide the answers you need to drive success.
Eurogentec
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010. Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments. Eurogentec has production sites in Europe and United States of America. The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines). | Founded in 1985 and part of Kaneka Corporation since 2010, Eurogentec is a leading biotechnology and CDMO company specializing in GMP-certified manufacturing of starting materials and APIs. With facilities in Europe and the USA, we support plasmid DNA, mRNA, recombinant proteins, peptides, antibody fragments, and therapeutic oligonucleotides from early research to clinical and commercial production. Our expertise in process development and scale-up ensures high-quality solutions at every stage. Detailed Description of Products (Event Specific) max 500 characters in English – Plasmid DNA : Starting material & APIs including Nano-plasmids & Minicircle DNA. FastTrack: 4-month production. – mRNA : IVT mRNA (0.1g–50g), saRNA, gRNA with co-/post-transcriptional modifications. – Proteins : GMP production in E. coli & P. pastoris for biotech & pharma. – Conjugates : Chemically modified recombinant proteins for clinical use. – Therapeutic Oligos : ASOs, siRNA, aptamers, CpG oligos. – Peptides : Linear, cyclic & complex-modified. – Antibody Fragments : scFv, Fab, VHH, bispecifics. | Eurogentec—part of Kaneka Corp. since 2010—is a leading international company founded in 1985 and headquartered in Belgium. Accredited by the Belgian AFMPS, US FDA, and Japanese MHLW, we deliver trusted solutions to the life sciences, molecular diagnostics, and therapeutic development sectors. As a major supplier in genomics (oligonucleotides, qPCR kits, reagents) and proteomics (custom and catalog antibodies, peptides), we also act as a reliable CDMO for process development and GMP manufacturing of vaccines and medicines—including therapeutic oligonucleotides, peptides, plasmids, recombinant proteins, mRNA and VHH antibodies. Our comprehensive services cover process transfer, development and optimization, scale-up, tox and clinical batches, GMP and GMP-like manufacturing, Quality Control, QA release, and ICH stability studies. From early-phase development to commercialization, Eurogentec is your single partner for every step of the journey.
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.
Daxiang Biotech
Daxiang Biotech is a leading innovator in organoid-on-a-chip technologies in China and a global provider of integrated microphysiological systems (MPS) solutions for drug discovery, translational research, and precision medicine. Founded in 2018, the company has established a fully integrated, end-to-end platform spanning design, modeling, R&D, manufacturing, and application of human-relevant in vitro systems. Powered by its core technology framework—Organoid-on-a-Chip + AI + Automation—Daxiang develops proprietary instruments, chips, reagents, and advanced human-relevant models to help global life sciences partners improve preclinical decision-making and accelerate development timelines. At the core of its technology is the IBAC® (Integrated Biomimetic Array Chip) platform, which integrates stem cell biology, organoid science, and microfluidics to recreate physiologically relevant human tissue environments in vitro. Based on this platform, Daxiang has developed 50+ organoid culture kits and 100+ humanized physiological and disease models across oncology, liver, gastrointestinal, kidney, brain, and cardiovascular applications. Daxiang’s technologies have been validated by third-party institutions and adopted by leading pharmaceutical companies, biotechnology companies, hospitals, and research institutes. The company has supported multiple IND-enabling programs, helping partners improve translational predictability and reduce reliance on animal models in selected applications. Daxiang Biotech is actively seeking global partnerships with pharmaceutical and biotech companies, CRO/CDMO organizations, research institutions, distributors, and strategic investors. Key collaboration interests include drug discovery services, translational model co-development, precision medicine applications, regional commercialization, and AI-enabled next-generation preclinical platforms.
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.